Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$0.24 - $3.04 $1,920 - $24,320
-8,000 Reduced 7.41%
100,000 $28,000
Q1 2024

May 10, 2024

BUY
$2.55 - $3.49 $127,499 - $174,500
50,000 Added 86.21%
108,000 $324,000
Q3 2023

Nov 13, 2023

SELL
$1.29 - $1.73 $64,500 - $86,500
-50,000 Reduced 46.3%
58,000 $87,000
Q1 2023

May 02, 2023

BUY
$1.25 - $4.05 $135,000 - $437,400
108,000 New
108,000 $136,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $16.8M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Sargent Investment Group, LLC Portfolio

Follow Sargent Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.